Trade MannKind

MannKind Corporation (NASDAQ: MNKD) focuses on the development and marketing of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently marketing Afrezza® (Human Insulin) Inhaling Powder, the company's first FDA-approved product and the only inhaled super-fast-acting insulin at meal time in the United States, where it is available by prescription from pharmacies across the country.